Cagrilintide

Cagrilintide is a long-acting amylin analog primarily utilized off-label for weight loss and appetite control, with limited evidence supporting its use in Type 2 diabetes management. Users typically report doses ranging from 13 µg to 6 mg, with 250 µg being the most common daily amount, while clinician-tier protocols suggest weekly subcutaneous doses between 250 µg and 2.4 mg. Nausea and gastrointestinal issues are the most frequently reported side effects, though these remain infrequent relative to total reports. Readers should note that the evidence base for non-diabetic indications is thinner than current discourse suggests, and no insurance pathway exists outside of Type 2 diabetes.

Half-life~7 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.42.83.23.32.84.0

Research Evidence

Evidence shape

Cagrilintide holds a moderate evidence tier, supported by nine published human studies primarily focused on diabetes and metabolic treatment. While the research landscape includes 40 registered trials, only one trial has posted results, leaving the vast majority of the 14 mapped indications in thin or exploratory stages. This discrepancy between the high volume of active, ongoing recruitment and the limited availability of published, blinded data indicates that while the peptide is under significant clinical investigation, the current evidence base remains largely unverified at scale.

Depthhow much
40 registered trials
24 completed · 1 with posted results · 16 recruiting / active · combined n=92
Breadthhow many areas
14 indications mapped
1 with results · 12 thin / exploratory · 1 animal-only · 7 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · AE table from NCT04982575 · 10 linked publications on registered trials
Breadth and depth57 rows captured
Human
direct clinical signal
49
Animal
translational support
3
In vitro
mechanistic support
5
HighMediumLow

Anecdotal efficacy

Cagrilintide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Nextgenpeps
USA
10 mg
$1.32
$0.13/mg
2
Bio Hack London
GB
100 mg
$87.23
$0.872/mg
3
Nurev Peptides
--
10 mg
$13.99
$1.4/mg
4
Adaptog Research
GB
1010 mg
$1,620.78
$1.61/mg
5
High Purity Peptides
Hong Kong
100 mg×10
$220.00
$2.2/mg
6
Mrbeetoe
--
50 mg
$110.00
$2.2/mg

price offers can be sorted by column

Some links are affiliate links. This never affects our rankings or inclusion.

1-6 of 187

CAGRILINTIDE dosing & protocol

How CAGRILINTIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 32
Typical dose
2.4 mg600 µg – 2.4 mg
typical
0
2 mg
4 mg
6 mg
distribution of 16 reported doses · darker = more
Frequency
weekly
Route
subQ

In the research trials, cagrilintide was administered subcutaneously weekly, with doses ranging from 600 mcg up to a typical 2.4 mg, as reported.

32 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Starting dose
250 µg250 µg – 2.4 mg
start
0
2 mg
4 mg
6 mg
distribution of 3 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
weekly
Route
subQ

In clinician practice, Cagrilintide is typically given as 2.4 mg subcutaneously once weekly, though regimens ranging from 0.25 mg to 2.4 mg weekly or a daily 2.4 mg dose have also been reported.

3 sources
Anecdotal
Community-reported real-world use · n = 38
Typical dose
250 µg12.5 µg – 6 mg
typical
0
2 mg
4 mg
6 mg
distribution of 42 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community users typically administer 250 mcg subcutaneously, with individual reports ranging from 12.5 mcg to 6 mg; no consistent dosing frequency or cycling pattern was noted.

38 sources

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604OrforglipronLiraglutideExenatideTesamorelinEloralintideMazdutideTesofensine